First private employer in Wallonia, GSK wishes to hire 250 new employees to expand its teams, particularly in the “vaccines” branch. For this purpose, the pharmaceutical company organizes a jobday with Forem on Tuesday March 15 in Nivelles, she announced Monday during a press conference on her Wavrian site. Registrations are open and compulsory. “We are currently looking for 250 collaborators, including 100 via Forem, to support the research and development of 20 vaccines (not yet available for patients), but also the production and worldwide export of our current portfolio (polio vaccines , measles, rotavirus, meningitis, flu, shingles, etc)”explique GSK.
Eleven profiles are in the line of fire. Among the jobs offered, “we find in particular technicians or managers in the fields of production, quality, maintenance, automation and safety”shells the company. “These are jobs in short supply, for which it is difficult to find candidates”, emphasizes Sylvia Chauvier, business advisor at Forem in Walloon Brabant. In this context, the organization of a recruitment day can act as a talent catalyst.
To apply, you must have a diploma adapted to the position or significant experience in a similar position. You should also register for jobday of March 15, which will be held at the Forem training center in Nivelles.
By embarking on new projects and through this recruitment campaign, is the pharma company looking to bounce back, when it was rather on the sidelines in the race for vaccines against Covid? “The objective is essentially to find good candidates to fill the jobs that are in short supply. We want these people to be able to join us and support us in our mission, which is to help everyone to be more active, to feel better. and live longersays Laurence Guiot, head of engineering and maintenance in Belgium at GSK. “So it’s not related to our commitment to Covid”she punctuates.
GSK has 9,000 employees in Belgium, mainly spread over the Brabant sites of Wavre and Rixensart. The group distributes nearly 600 million doses of vaccines in more than 160 countries. It is part of a pharmaceutical sector that has shown dizzying growth of 83% in Walloon Brabant over the past 10 years.
On the front of Russian-Ukrainian news, GSK, which says it supports global sanctions, has chosen to adopt a “precautionary attitude” to avoid any involvement with the authorities in Moscow: “For example, we are stopping all publicity and will not conclude no contract that directly supports the administration or the Russian army,” she warns. “We do not have a production plant in Russia, only a small vaccine packaging unit (in Moscow). However, we will continue to deliver our vaccines to this country, for public health reasons. It would be harmful to to see certain diseases reappear on a planetary scale… And we want to believe in access to health care for all. However, we are linked to our logistics partners in terms of supply. The situation does not depend solely on us and things are changing rapidly on the spot”, further specifies the company.